hematopoietic stem News
-
Abbott Molecular distribution of ELITechGroup products will expand distribution channels
ELITechGroup today announced a distribution agreement with Abbott Molecular, Inc. for U.S. distribution of molecular diagnostic reagents. The reagents included in the agreement are focused on monitoring virus activity in patients that have undergone organ or hematopoietic stem cell transplantation. Other products included in the agreement will focus on the expanding need to test for additional ...
By ELITechGroup
-
Genenta to Host Expert Fireside Chat on Immuno Gene & Cell Therapy for Treatment of Solid Tumors
Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, announced it will hold a webinar entitled "Expert Perspectives: Immuno Gene & Cell Therapy for the Treatment of Solid Tumors" on Thursday, April 28, 2022 at 8:00 AM EDT / 2:00 PM CET. In this fireside chat, Genenta is ...
-
Genenta Files Annual Report on Form 20-F for Fiscal Year 2021
Genenta Science S.p.A. (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, today announced it filed its annual report on Form 20-F for the fiscal year ended December 31, 2021 with the Securities and Exchange Commission ("SEC") on May 2, 2022. The annual report can be accessed on the Company's ...
-
SQZ Biotechnologies Announces Integrated Point-ofCare Cell Therapy Manufacturing System Demonstrated Comparable or Better Performance Than a More Conventional Clean Room-Based Process
WATERTOWN, Mass.--(BUSINESS WIRE)-- SQZ Biotechnologies (NYSE: SQZ) announced today that the company’s rst generation, integrated point-of-care (POC) cell therapy manufacturing system demonstrated superior process performance and comparable or improved product specications relative to current clean room-based processes used in clinical development. The non-clinical studies showed that the ...
-
Genenta Appoints Industry Veteran Tim Obara as Head of Business Development
Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, announces the appointment of Tim Obara, a highly experienced commercial healthcare executive, as Vice President Business Development. Tim has significant experience across a broad range of therapeutic areas and with global ...
-
Genenta Closes Its Upsized Initial Public Offering of American Depository Shares
Genenta Science S.p.A. (Nasdaq: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for solid tumors, including the lead product candidate, Temferon™, announced today the closing of its upsized initial public offering of 2.4 million American Depositary Shares (“ADSs”) at a public offering price of ...
-
Genenta announces filing of registration statement for proposed initial public offering
Genenta Science, a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer (Temferon™), announced today that it has filed a registration statement on Form F-1 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public ...
-
Creative Proteomics Cytokine Accelerates Your Project with Its Colony Stimulating Factor Detection Service
The Cytokine division belongs to Creative Proteomics, which specializes in providing cytokine research and analysis services for researchers in the pharmaceutical and biotechnology industries, as well as academic institutes and government agencies. Creative Proteomics Cytokine recently announced the launch of the colony stimulating factor detection platform for scientific research. ...
-
Editas Medicine Announces Positive Initial EDIT-301 Safety And Efficacy Data From The First Four Patients Treated In The RUBY Trial And The First Patient Treated In The EdiTHAL Trial
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced positive initial safety and efficacy data from the first four patients with sickle cell disease (SCD) treated with EDIT-301 in the RUBY trial and from the first transfusion-dependent beta thalassemia patient treated in the EdiTHAL trial. The RUBY trial data will be presented in an oral presentation at ...
-
Tactiva Therapeutics Co-Founder Kunle Odunsi Elected to National Academy of Medicine
BUFFALO, N.Y., October 16, 2018 — Tactiva Therapeutics, a development stage company targeting a broad range of cancers, announced today that its co-founder Kunle Odunsi, M.D., Ph.D., FRCOG, FACOG, is among the 75 newly elected regular members of the National Academy of Medicine (NAM). Membership of the NAM is considered one of the highest honors in the field of health and medicine and ...
-
Genenta Progresses to Higher Dosing Cohort in Temferon™ Phase 1/2a Clinical Trial in Glioblastoma Multiforme
Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, announces that its ongoing trial of Temferon™ in glioblastoma multiforme patients who have an unmethylated MGMT gene promoter (uMGMT-GBM) has escalated to the next planned dose. With no drug-limiting toxicities observed at ...
-
Genenta Data Presentation at AACR to Describe On-Target Biological Activity of Temferon™ in Unmethylated Glioblastoma Multiforme
Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, will present clinical data from its Phase 1/2a dose-escalation study of its clinical-stage candidate Temferon™ in patients with glioblastoma multiforme (GBM) who have an unmthylated MGMT gene promotor (uMGMT-GBM) at the ...
-
Genenta ASGCT Clinical Data Highlights Temferon™ Biological Effects in Glioblastoma
Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, announces that preliminary findings from its Phase 1/2a of Temferon™ in the treatment of patients with glioblastoma multiforme patients who have an unmethylated MGMT gene promoter (uMGMT-GBM) provide initial evidence of ...
-
Genenta Announces Nomination of Mark A. Sirgo as Chair
Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, announced the nomination of Mark A. Sirgo, PharmD, an executive leader with over 35 years of pharmaceutical industry experience, as its new Chair. Stephen Squinto, PhD is stepping down from his role as Chair on May 1, 2022 to ...
-
Saneron and USF Patent Method for Umbilical Cord Blood Cell Use
Researchers at Saneron CCEL Therapeutics, Inc. of Tampa, Florida, (www.saneron-ccel.com) and the University of South Florida have received a patent relating to a method for obtaining and using umbilical cord blood cells from a donor or patient to provide neural cells for transplantation aimed at repairing a variety of neurodegenerative diseases of the brain and spinal cord, such as ...
-
Forge Reports Positive Clinical Data on Brain Development and Motor Function from the RESKUE Novel Phase 1/2 Gene Therapy Trial in Patients with Krabbe Disease at the SSIEM Annual Symposium
FBX-101 clinical data demonstrating safety and initial efficacy from the RESKUE trial is being presented at the 2022 Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium FBX-101 is a systemic AAV gene therapy following unrelated cord blood transplantation (“UCBT”) and has been well tolerated through Day 180 FBX-101 significantly increased GALC enzyme ...
-
Optimal oxygen levels for specific stem cell types
Hypoxia maintains the niche where stem cells stay in optimal condition that benefits the self-renewal capacities of human embryonic, mesenchymal, hematopoietic and neural stem cells. In research setting it is very important to understand that the results of any given experiment are only as good as the methods they were produced with. In stem cell biology this is exceptionally important as low ...
By Baker
-
Protecting the Immunocompromised from Invasive Mold Infection Risks in Hospitals and Buildings throughout Puerto Rico
Anyone with a weakened or suppressed immune system could be at heightened risk of developing an invasive mold infection. The Centers for Disease Control and Prevention (CDC) warns that these types of infections can occur days to weeks after exposure to fungi that live in the environment. The agency goes so far as to advise physicians to keep invasive mold infections in mind when treating people ...
-
Forge Biologics Announces Updated Positive Clinical Data in RESKUE, a Novel Phase 1/2 Gene Therapy Trial for Patients with Krabbe Disease
Clinical data demonstrating initial safety and efficacy from the RESKUE trial are being presented by Chief Medical Officer Maria Escolar, M.D., at the 29th Congress of European Society of Gene & Cell Therapy (ESGCT), October 11-14, 2022 Subjects treated with FBX-101 have shown increased galactocerebrosidase (GALC) enzyme activity in plasma and cerebrospinal fluid (CSF), normal white matter ...
-
Dako, an Agilent Technologies Company, Launches Two Ready-to-Use Antibodies for Cancer Diagnosis
Dako, an Agilent Technologies company and worldwide provider of cancer diagnostic solutions, today announced the addition of two new antibodies, Anti-CK 8/18 and Anti-TdT, to the Dako portfolio of high-quality reagents, instruments and software. Anti-CK 8/18 is the first rabbit monoclonal antibody cocktail for cytokeratin 8/18 (CK 8/18) available from a major pathology provider. It is used by ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you